Global /United States /Healthcare /Drug Manufacturers - General /NERV

Minerva Neurosciences, Inc.

NERV

• NASDAQ: NERV • Delayed

6.39USD -0.8%

As of 13 June 2026, Minerva Neurosciences, Inc. has a market cap of $280.15M USD, ranking #18996 globally and #3157 in the United States. It ranks #1713 in the Healthcare sector, and #627 in the Drug Manufacturers - General industry.

Global Rank

18996

Country Rank

3157

Sector Rank

1713

Industry Rank

627

Key Stats

Market Cap

$280.15MUSD

Enterprise Value

$260.04MUSD

EBITDA (TTM)

-$15.1MUSD

Net Income (TTM)

-$293.42MUSD

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Remy Luthringer open_in_new

Employees

Founded

2007

IPO

01 Jul 2014

Website

minervaneurosciences.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	-13%	3.4%	53%	39%	59%	257%	128%	-68%

News

NERV Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	NERV Minerva Neurosciences Inc ISIN: US6033802058 Shares Out.: Shares Outstanding: 46.589M¹ Shares Float: 37.067M² TV: TradingView: NASDAQ: NERV SA: Stock Analysis: NASDAQ: NERV YF: Yahoo Finance: NERV GF: Google Finance: NASDAQ: NERV NQ: NASDAQ: NERV BA: Barron's: NERV MS: Morningstar: XNAS: NERV	6.39 USD	TV: TradingView: NASDAQ: NERV SA: Stock Analysis: NASDAQ: NERV YF: Yahoo Finance: NERV GF: Google Finance: NASDAQ: NERV NQ: NASDAQ: NERV BA: Barron's: NERV MS: Morningstar: XNAS: NERV

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 272K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 195K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 129K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 98K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 53K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 42K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 115K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 103K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 98K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 65K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 39K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 39K%	14.6	United Kingdom

chevron_leftBack